Iomab-ACT: A Pilot Study of 131-I Apamistamab (Iomab-B) Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Conditions: B-ALL; DLBCL; B ALL; Dlbcl-Ci; DLBCL Unclassifiable; DLBCL, Nos Genetic Subtypes; DLBCL Activated B-Cell Type; DLBCL Germinal Center B-Cell Type; Diffuse Large B-cell Lymphoma; HGBL; HGBL, Nos Interventions: Drug: 131-I Apamistamab; Biological: CAR T-cell Sponsors: Memorial Sloan Kettering Cancer Center; Actinium Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Research | Study